Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Ticker
REGN
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$98.52B
52-week range
$591.52 - $991.73

Valuation

Share price
$952.40 (close of Nov 16, 2026)
P/E (TTM)
20.29x
Price to book
2.94x
Price to free cash flow
25.75x
Enterprise value
$97.57B
Book value per share
$323.82

Price performance

PeriodChange
1 day-0.32%
5 days+3.53%
1 month+20.44%
3 months+18.53%
6 months+36.40%
Year to date+23.39%
1 year+37.33%
3 years+19.57%
5 years+48.18%
10 years+126.72%
All time+4,408.40%

Short interest

As of
Oct 30, 2026
Short % of float
2.30%
Shares short
2.22M
Days to cover
2.73
Change since prior report
+3.85%
Source
FINRA consolidated short interest

Members of Congress who disclosed REGN trades

Julie Johnson · Robert Bresnahan · Byron Donalds · Gilbert Ray Cisneros · Alan Armstrong · Jefferson Shreve · Josh Gottheimer · Julia Letlow

Super investors holding REGN

Dodge & Cox (Dodge & Cox Funds) · Mason Hawkins (Southeastern Asset Management) · Harry Burn (Sound Shore Management) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
14.41%
Return on invested capital
8.40%
Return on assets
11.11%
Return on capital employed
9.89%
Gross margin
84.56%
Net margin
31.41%
EBITDA margin
28.74%
Revenue growth
0.99%
Net income growth
2.09%
Free cash flow growth
11.35%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.88%
Current ratio
3.35x
Net debt to EBITDA
-0.15x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$14.34B
Cost of revenue
$2.21B
Gross profit
$12.13B
EBITDA
$4.12B
Net income
$4.50B
Earnings per share
$43.07
Research and development
$5.85B
Interest expense
$43.80M
Shares outstanding
104.60M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$14.34B$12.13B$4.50B$43.07
2024-12-31$14.20B$12.08B$4.41B$40.90
2023-12-31$13.12B$11.12B$3.95B$37.05
2022-12-31$12.17B$10.45B$4.34B$40.51
2021-12-31$16.07B$13.63B$8.08B$76.40
2020-12-31$8.50B$7.57B$3.51B$32.65
2019-12-31$6.56B$6.15B$2.12B$19.38
2018-12-31$5.15B$4.91B$2.44B$22.65
2017-12-31$5.87B$5.67B$1.20B$11.27
2016-12-31$4.86B$4.67B$895.50M$8.55

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3184.56%31.41%14.41%8.40%
2024-12-3185.04%31.07%15.03%11.30%
2023-12-3184.75%30.14%15.22%13.26%
2022-12-3185.82%35.64%19.14%16.63%
2021-12-3184.82%50.25%43.03%35.85%
2020-12-3189.08%41.35%31.86%23.90%
2019-12-3193.86%32.26%19.08%16.04%
2018-12-3195.38%47.50%27.91%27.69%
2017-12-3196.55%20.41%19.51%19.52%
2016-12-3196.00%18.42%20.13%20.15%

Cash and debt by year

Period endCashDebt
2025-12-31$3.12B$1.99B
2024-12-31$2.49B$1.98B
2023-12-31$2.73B$1.98B
2022-12-31$3.11B$1.98B
2021-12-31$2.89B$1.98B
2020-12-31$2.19B$1.98B
2019-12-31$1.62B-
2018-12-31$1.47B-
2017-12-31$812.70M-
2016-12-31$535.20M-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$4.08B$993.70M
2024-12-31$3.66B$982.80M
2023-12-31$3.88B$885.00M
2022-12-31$4.42B$725.00M
2021-12-31$6.53B$601.70M
2020-12-31$2.00B$432.00M
2019-12-31$2.00B$464.30M
2018-12-31$1.81B$427.40M
2017-12-31$1.03B$507.30M
2016-12-31$974.00M$559.90M

Dividend history

Most recent payment
Aug 18, 2026
Paid in the last twelve months
$3.70
Payment dateDividend per share
2026-08-18$0.94
2026-05-20$0.94
2026-02-20$0.94
2025-11-20$0.88
2025-08-18$0.88
2025-05-20$0.88
2025-02-20$0.88

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-30Sep 2026$13.76
2026-07-30Jun 2026$8.00
2026-04-29Mar 2026$6.28
2026-01-30Dec 2025$8.28
2025-10-28Sep 2025$7.52
2025-08-01Jun 2025$6.09
2025-04-29Mar 2025$6.61
2025-02-04Dec 2024$9.62

Filings and sources

Company website
regeneron.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Moderna, Inc. (MRNA) · Vertex Pharmaceuticals Inc (VRTX) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · ICON plc (ICLR) · Charles River Laboratories International, Inc. (CRL) · Revvity, Inc. (RVTY)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades